SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-24-021945
Filing Date
2024-05-09
Accepted
2024-05-09 07:05:15
Documents
92
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q akba-20240331.htm   iXBRL 10-Q 1804445
2 EX-10.11 exhibit1011akebia_separati.htm EX-10.11 55812
3 EX-31.1 exhibit311-q12024.htm EX-31.1 11010
4 EX-32.1 exhibit321-q12024.htm EX-32.1 6209
10 GRAPHIC akba-20240331_g1.gif GRAPHIC 3995
  Complete submission text file 0001628280-24-021945.txt   8807843

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT akba-20240331.xsd EX-101.SCH 79548
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT akba-20240331_cal.xml EX-101.CAL 82775
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT akba-20240331_def.xml EX-101.DEF 356833
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT akba-20240331_lab.xml EX-101.LAB 818783
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT akba-20240331_pre.xml EX-101.PRE 584879
96 EXTRACTED XBRL INSTANCE DOCUMENT akba-20240331_htm.xml XML 1003612
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36352 | Film No.: 24928499
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)